Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02420873 · ClinicalTrials.gov registry record · Phase 2
An Open-label Phase II Study of Lorvotuzumab Mertansine
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT02420873: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT02420873 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02420873, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if lorvotuzumab mertansine can help to control blood cancers that have the CD56 tumor marker. The safety of this drug will also be studied.
Primary Outcome
ORR, defined as CR (complete remission) + CRp (complete remission with incomplete platelet recovery) + CRi (complete remission with incomplete count recovery) within 3 cycles of therapy with IMGN901.
Interventions
- DRUG Lorvotuzumab Mertansine (IMGN901)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-05-12 |
| Est. Completion | 2017-06-06 |
| Phase | Phase 2 |
What the finished NCT02420873 record still lists
NCT02420873 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which Lorvotuzumab Mertansine (IMGN901) is the first listed.
NCT02420873 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02420873 about?
NCT02420873 is a clinical study titled "An Open-label Phase II Study of Lorvotuzumab Mertansine". The goal of this clinical research study is to learn if lorvotuzumab mertansine can help to control blood cancers that have the CD56 tumor marker. The safety of this drug will also be studied.
What is the current status of trial NCT02420873?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2015-05-12. Estimated completion is 2017-06-06.
What interventions are being tested in trial NCT02420873?
The interventions under investigation include: Lorvotuzumab Mertansine (IMGN901) (DRUG).
Who is sponsoring clinical trial NCT02420873?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02420873's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI